TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2404388

Group type: EXPERIMENTAL
Intervention: 200,000 IU streptokinase
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 750,000 IU streptokinase
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 1,500,000 IU streptokinase
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: 3,000,000 IU streptokinase
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: All doses of streptokinase
Number of subjects: 189
Study: 656266

Group type: EXPERIMENTAL
Intervention: Propranolol (n=7)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Methyldopa (n=6)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 21
Study: 6356901

Group type: EXPERIMENTAL
Intervention: Labetalol alone (100 to 1,200 mg twice a day)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Labetalol in combination with a diuretic
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Labetalol (with or without diuretic)
Number of subjects: 337
Study: 31783766

Group type: EXPERIMENTAL
Intervention: Pelvic intensity‐modulated radiation therapy (IMRT) of 50 Gy/25Fx concurrently with capecitabine and oxaliplatin (Arm A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pelvic radiation of 50 Gy/25Fx with a concomitant boost of 5 Gy to the primary lesion, followed by a cycle of XELOX 2 weeks after the end of CRT (Arm B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Arm A
Number of subjects: 120

Group type: COMPARATOR
Intervention: Arm B
Number of subjects: 120
Study: 28859184

Group type: EXPERIMENTAL
Intervention: Blepharoplasty
Number of subjects: 401
Study: 27039894

Group type: EXPERIMENTAL
Intervention: Light‐emitting diode‐mediated‐photobiomodulation therapy (LPT) applied with an energy density of 20 mW/cm2 for 21 successive days (20 minutes per day) over the movement of canine teeth.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Light‐emitting diode‐mediated‐photobiomodulation therapy (LPT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (placebo application of LPT)
Number of subjects: 20
Study: 24215032

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) injections (1.25 mg/0.05 mL)
Number of subjects: 105
Study: 22504600

Group type: EXPERIMENTAL
Intervention: Monthly oral periodic presumptive treatment (PPT; 2 g metronidazole + 150 mg fluconazole)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 19422409

Group type: EXPERIMENTAL
Intervention: US-assisted femoral nerve block (FNB)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Fascial pop (FP) technique
Number of subjects: 67
Study: 17470024

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouthwash
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine spray
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine spray
Number of subjects: 90
Study: 15533734

Group type: EXPERIMENTAL
Intervention: C12 peptide with higher dose of alginic acid (1754 mg)
Number of subjects: 10
Study: 11973116

Group type: EXPERIMENTAL
Intervention: Telephone interventions (two telephone contacts in addition to treatment as usual)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Treatment as usual (no telephone interventions)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Telephone interventions
Number of subjects: 216
Study: 9717819

Group type: EXPERIMENTAL
Intervention: 1.5 mg/m2 9‐AC p.o. on day 1
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1.0 mg/m2 9‐AC i.v. on day 8
Number of subjects: 12
Study: 8127017

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 50
Study: 2573371

Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg tertatolol with 1 g aspirin
Number of subjects: 8

Group type: COMPARATOR
Intervention: 1 g aspirin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 3279

Group type: EXPERIMENTAL
Intervention: L-prolyl-Lleucyl-glycine amide (PLG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31596213

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (MAD)
Number of subjects: 85
Study: 27986405

Group type: EXPERIMENTAL
Intervention: 1-h post-load plasma glucose <155 mg/dl
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 1-h post-load plasma glucose ≥155 mg/dl
Number of subjects: 34
Study: 25705332

Group type: EXPERIMENTAL
Intervention: HA/DBM mixture in a PEEK cage
Number of subjects: 85

Group type: COMPARATOR
Intervention: HA/TCP mixture in a PEEK cage
Number of subjects: 85
Study: 23670707

Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/day
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21996984

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (300,000 IU/month)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 31
Study: 19545297

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 2 times per week
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 3 times per week
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 5 times per week
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied 7 times per week
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 149
Study: 17548542

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 28
Study: 15570929

Group type: EXPERIMENTAL
Intervention: Jelco plus
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insyte autoguard
Number of subjects: 40

Group type: COMPARATOR
Intervention: All other catheters (Supercath, Introcan safety, Surshield surflo II, Safetouch cath, Protective plus, Acuvance plus)
Number of subjects: 40
Study: 10817120

Group type: EXPERIMENTAL
Intervention: FTND score > or =8
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: RTQ score > or =28
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: FTND criteria
Number of subjects: 991

Group type: EXPERIMENTAL
Intervention: RTQ criteria
Number of subjects: 991
Study: 8841302

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: No cryotherapy (control)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Cryotherapy (treated eyes)
Number of subjects: 153

Group type: COMPARATOR
Intervention: No ROP (control group)
Number of subjects: 153
Study: 1475090

Group type: EXPERIMENTAL
Intervention: 0.5 ml of 1% acetylcholine chloride
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 40
Study: 6397852

Group type: EXPERIMENTAL
Intervention: Programmed physical training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flunarizine 5 mg b.i.d. during double-blind, cross-over medication period
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo during double-blind, cross-over medication period
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oxygen tension measurements
Number of subjects: 12
Study: 30725387

Group type: EXPERIMENTAL
Intervention: Non-selective antimuscarinic drugs (trospium chloride, tolterodine tartrate, fesoterodine fumarate, propiverine hydrochloride)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Selective antimuscarinic drugs (darifenacin hydrobromide, solifenacin succinate, oxybutynin hydrochloride)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Trospium chloride
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tolterodine tartrate
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Fesoterodine fumarate
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride
Number of subjects: 250
Study: 29663714

Group type: EXPERIMENTAL
Intervention: Mirogabalin (10-40 mg single dose; 10, 15 mg twice a day repeated doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27333407

Group type: EXPERIMENTAL
Intervention: 6.6 g Fortetropin supplementation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 19.8 g Fortetropin supplementation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fortetropin plus exercise
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control plus exercise
Number of subjects: 45
Study: 25697893

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (O3FAs) - 2 capsules daily containing 180mg EPA and 120mg DHA for 3 months
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo - 2 capsules of olive oil daily for 3 months
Number of subjects: 478
Study: 23623487

Group type: EXPERIMENTAL
Intervention: Plastic adhesive drape
Number of subjects: 140

Group type: COMPARATOR
Intervention: Bare skin
Number of subjects: 140
Study: 20578379

Group type: EXPERIMENTAL
Intervention: Vessel pricking therapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prednisone (oral administration)
Number of subjects: 70
Study: 19002265

Group type: EXPERIMENTAL
Intervention: gemcitabine plus docetaxel
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: cisplatin-based second-line therapy
Number of subjects: 102
Study: 16877897

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs) - fluoxetine or paroxetine (20 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Duloxetine in elderly patients
Number of subjects: 9
Study: 14564329

Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 1926
Study: 10827368

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 to 2.5 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study: 9159196

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrosigmoidography (TC‐ESG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intra-sigmoid electrosigmoidography (IS‐ESG)
Number of subjects: 24
Study: 1629506

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (ALB) with inhaled beclomethasone dipropionate (BDP)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (ALB) with oral theophylline (THEO)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Inhaled albuterol (ALB), inhaled BDP, and oral THEO
Number of subjects: 111
Study: 6333247

Group type: EXPERIMENTAL
Intervention: Low dose mediastinal radiation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Combination chemotherapy and radiotherapy (without low dose mediastinal radiation)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall treatment (combination chemotherapy and radiotherapy)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: T leukaemia patients with WCC greater than 100 x 10(9)1(‐1)
Number of subjects: 82
Study: 31028232

Group type: EXPERIMENTAL
Intervention: Model incorporating predictors of lung cancer probability
Number of subjects: 1994

Group type: EXPERIMENTAL
Intervention: Risk model for lung cancer probability
Number of subjects: 1994
Study: 30145941

Group type: EXPERIMENTAL
Intervention: Lorcaserin (10 mg twice daily)
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000
Study: 26829011

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 2489

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 2489
Study: 24327173

Group type: EXPERIMENTAL
Intervention: Single eye-drop containing 0.0175, 0.175, or 0.7 μg rhNGF
Number of subjects: 74

Group type: COMPARATOR
Intervention: Single ascending dose of rhNGF eye drops three times a day for 1 day (total daily dose 2.1, 6.3, or 18.9 μg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Multiple ascending dose of rhNGF eye drops three times a day for 5 days (total dose 10.5, 31.5, or 94.5 μg)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 74
Study: 22364387

Group type: EXPERIMENTAL
Intervention: 12 week exercise program including aerobic and strengthening exercises, conducted between 20 and 36 weeks of pregnancy, with one weekly group session led by physiotherapists and home exercises encouraged twice a week
Number of subjects: 855

Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 855
Study: 20683461

Group type: EXPERIMENTAL
Intervention: Free fruit program
Number of subjects: 103
Study: 18363294

Group type: EXPERIMENTAL
Intervention: Register study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized clinical trial
Number of subjects: 0
Study: 15753847

Group type: EXPERIMENTAL
Intervention: Higher C2 target range (1,000-1,200 ng/mL for months 4-6 and 800-1,000 ng/mL for months 7-12)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Lower C2 target range (800-1,000 ng/mL for months 4-6 and 600-800 ng/mL for months 7-12)
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Both higher and lower C2 target ranges
Number of subjects: 296
Study: 12762475

Group type: EXPERIMENTAL
Intervention: Photocolorimetric analysis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional visual assessment
Number of subjects: 40
Study: 10559813

Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of normal saline (NS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intracoronary infusion of lactated Ringer's solution (LR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Intracoronary infusion of lactated Ringer's solution with 5% dextrose (D5LR)
Number of subjects: 34
Study: 7904931

Group type: EXPERIMENTAL
Intervention: Propranolol (non-selective with no ISA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-1-selective with no ISA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Pindolol (non-selective with ISA)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3551618

Group type: EXPERIMENTAL
Intervention: Pilocarpine gel
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% solution
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Timolol 0.5% solution
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 80
Study: 31647503

Group type: EXPERIMENTAL
Intervention: Pertuzumab, trastuzumab, and docetaxel
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo, trastuzumab, and docetaxel
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 29446970

Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0

Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participants
Number of subjects: 0
Study: 26814889

Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling (SCC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (no SCC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attendees of stop-smoking counseling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 0
Study: 25533223

Group type: EXPERIMENTAL
Intervention: Modified Agatston score strata of 1 to 10
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Modified Agatston score strata of 11 to 100
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Modified Agatston score strata of 101 to 400
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Modified Agatston score strata of >400
Number of subjects: 3559

Group type: COMPARATOR
Intervention: Model with age, pack‐years, smoking status, and modified Agatston score strata
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Adding the number of calcifications to the model with age, pack‐years, smoking status, and modified Agatston score strata
Number of subjects: 3559

Group type: EXPERIMENTAL
Intervention: Volume of the largest calcification
Number of subjects: 3559
Study: 22882084

Group type: EXPERIMENTAL
Intervention: Start For Life treatment (30 minutes daily of structured physical activity with behavioral and self-regulatory skills training)
Number of subjects: 338

Group type: EXPERIMENTAL
Intervention: Start For Life treatment
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual-care control condition
Number of subjects: 338
Study: 21598057

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (target 4.4‐6.1 mmoL·L(‐1) or 80‐110 mg·dL(‐1))
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 364

Group type: COMPARATOR
Intervention: Conventional glucose control (target 10‐11.1 mmoL·L(‐1) or 180‐200 mg·dL(‐1))
Number of subjects: 364
Study: 19349306

Group type: EXPERIMENTAL
Intervention: First-episode psychosis (FEP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrahigh-risk individuals (UHRP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ultrahigh-risk individuals (UHRP) and first-episode psychosis (FEP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ultrahigh-risk non-psychotic individuals (UHRNP)
Number of subjects: 80
Study: 16685055

Group type: EXPERIMENTAL
Intervention: Soymilk (71.6 mg isoflavones from 706 mL soymilk/d)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Supplement (70 mg isoflavones in a supplement plus 706 mL cow milk/d)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (706 mL cow milk/d plus a placebo supplement)
Number of subjects: 52
Study: 15300729

Group type: EXPERIMENTAL
Intervention: Microwave stimulation (450 MHz, 7 Hz on‐off modulation, 0.16 mW/cm2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Photic stimulation
Number of subjects: 20
Study: 11780680

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ) 60 mg orally twice daily for 12 weeks
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 9871866

Group type: EXPERIMENTAL
Intervention: Topographic parameters computed by the HRT
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Principal component analysis of topometric parameters
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Interocular differences in topographic parameters
Number of subjects: 225
Study: 8030848

Group type: EXPERIMENTAL
Intervention: Antagonic-Stress (AS)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Meclofenoxate (MF)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Nicergoline (NE)
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 343
Study: 2643038

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham sphincterotomy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 47
Study: 30531312

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28225508

Group type: EXPERIMENTAL
Intervention: Patients with a suicide attempt within the last 3 months
Number of subjects: 228

Group type: COMPARATOR
Intervention: Patients with suicidal thoughts but no attempts
Number of subjects: 228
Study: 25167840

Group type: EXPERIMENTAL
Intervention: PEX168 50μg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PEX168 100μg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PEX168 200μg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PEX168 300μg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PEX168
Number of subjects: 50
Study: 23453459

Group type: EXPERIMENTAL
Intervention: Anakinra (100 mg/day for 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined data from both groups
Number of subjects: 30
Study: 21642851

Group type: EXPERIMENTAL
Intervention: Systemic sclerosis (SSc) patients
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison of SSc patients and control subjects
Number of subjects: 37
Study: 18371034

Group type: EXPERIMENTAL
Intervention: Surfactant replacement therapy (bovine lung surfactant extract) with standard treatment for RDS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard care for RDS without surfactant therapy
Number of subjects: 27
Study: 16423747

Group type: EXPERIMENTAL
Intervention: Positive pre-event stereotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative misinformation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recollection for negative misinformation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Familiarity for positive misinformation
Number of subjects: 0
Study: 14519175

Group type: EXPERIMENTAL
Intervention: Bupropion (sustained-release)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Non-menthol smokers
Number of subjects: 600
Study: 10949981

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (320 mg once-daily for 5 days)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg three-times daily for 7 days)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Gemifloxacin
Number of subjects: 600

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate
Number of subjects: 600
Study: 9171971

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) and resistance exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Re-training after 12 weeks of detraining
Number of subjects: 11
Study: 8160567

Group type: EXPERIMENTAL
Intervention: Theophylline (T)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 9
Study: 3769187

Group type: EXPERIMENTAL
Intervention: Intravenous dipyridamole (0.24 mg/kg/hr)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No dipyridamole (control group)
Number of subjects: 40
Study: 29440219

Group type: EXPERIMENTAL
Intervention: Keratin dressings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care non-medicated dressings
Number of subjects: 0